Sustained release of 5-fluorouracil from ethylene acetate copolymer.
Pharmacologic inhibition of fibroblast proliferation and scar formation remains an important consideration in many ophthalmologic surgical procedures. Such inhibition is particularly important in glaucoma filtration surgery. A sustained release system for 5-fluorouracil (5-FU) using ethylene vinyl acetate copolymer (Elvax) was characterized in vitro. 5-FU was incorporated into Elvax discs of 4 mm diameter. Discs were coated to allow sustained and predictable release over a 14 day period. Alteration of coatings, which act as rate-controlling membranes, allowed variation in the pattern of 5-FU release from the core which acts as the drug reservoir. This system for the sustained release of 5-FU may prove valuable in glaucoma surgery where the suppression of cellular proliferation is desired. The non-inflammatory nature of Elvax suggests this compound may provide an alternative means of 5-FU delivery.
Wyszynski
R E
RE
Veterans Administration Medical Center, Case Western Reserve University, Cleveland, Ohio.
Vahey
J B
JB
Manning
L
L
Bruner
W E
WE
Morgan
K M
KM
Burney
E N
EN
D003692:Delayed-Action Preparations; D005472:Fluorouracil / Q000008:administration & dosage*; D014677:Pharmaceutical Vehicles; D011145:Polyvinyls
D003692:Delayed-Action Preparations; D014677:Pharmaceutical Vehicles; D011145:Polyvinyls; C016438:ethylenevinylacetate copolymer; D005472:Fluorouracil